ELIZABETH SEELHORST: Open Payments
NPI 1932746054 · CORYDON, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,941 in 97 payments from 34 companies in 2025. Trend: 2023 $643 · 2024 $1,264 · 2025 $1,941
Food & beverage: $1,941
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 12 | $222 |
| Celgene Corporation | 9 | $215 |
| Novartis Pharmaceuticals Corporation | 11 | $214 |
| ABBVIE INC. | 8 | $176 |
| Incyte Corporation | 4 | $100 |
| Janssen Biotech, Inc. | 5 | $95 |
| PharmaEssentia USA Corporation | 4 | $80 |
| E.R. Squibb & Sons, L.L.C. | 4 | $65 |
| TerSera Therapeutics LLC | 2 | $54 |
| Genmab U.S., Inc. | 2 | $52 |
Products named: REBLOZYL, Fabhalta, VENCLEXTA, IBRANCE, BESREMI, OPDIVO, KISQALI, EPKINLY.
Industry payments across IN — which companies pay providers there.
